NICE Endorses Eli Lilly’s Psoriasis Therapy Taltz

November 3, 2016

The UK’s cost watchdog is recommending reimbursement for Eli Lilly’s Taltz for severe plaque psoriasis when standard treatment options are ineffective, provided the company discounts the price.

The National Institute for Health and Care Excellence concluded that Taltz is more clinically effective than Amgen’s Enbrel and generally well-tolerated.

The recommendation stipulates that treatment will be offered at an undisclosed discount price and will be discontinued after 12 weeks if the psoriasis has not responded adequately.

View today's stories